LONDON-- AstraZeneca PLC (AZN.LN) Monday announced a deal giving TerSera Therapeutics LLC commercial rights to its prostate cancer treatment Zoladex in the U.S. and Canada.

TerSera will pay AstraZeneca $250 million on completion, plus up to $70 million depending on sales figures and recurring quarterly sales-based payments at mid-teen percentage of product sales.

-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan

(END) Dow Jones Newswires

February 20, 2017 02:24 ET (07:24 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Astrazeneca Charts.